Advertisement

Alcohol Consumption and Antitumor Immunity: Dynamic Changes from Activation to Accelerated Deterioration of the Immune System

  • Hui Zhang
  • Zhaohui Zhu
  • Faya Zhang
  • Gary G. Meadows
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 815)

Abstract

The molecular mechanisms of how alcohol and its metabolites induce cancer have been studied extensively. However, the mechanisms whereby chronic alcohol consumption affects antitumor immunity and host survival have largely been unexplored. We studied the effects of chronic alcohol consumption on the immune system and antitumor immunity in mice inoculated with B16BL6 melanoma and found that alcohol consumption activates the immune system leading to an increase in the proportion of IFN-γ-producing NK, NKT, and T cells in mice not injected with tumors. One outcome associated with enhanced IFN-γ activation is inhibition of melanoma lung metastasis. However, the anti-metastatic effects do not translate into increased survival of mice bearing subcutaneous tumors. Continued growth of the subcutaneous tumors and alcohol consumption accelerates the deterioration of the immune system, which is reflected in the following: (1) inhibition in the expansion of memory CD8+ T cells, (2) accelerated decay of Th1 cytokine-producing cells, (3) increased myeloid-derived suppressor cells, (4) compromised circulation of B cells and T cells, and (5) increased NKT cells that exhibit an IL-4 dominant cytokine profile, which is inhibitory to antitumor immunity. Taken together, the dynamic effects of alcohol consumption on antitumor immunity are in two opposing phases: the first phase associated with immune stimulation is tumor inhibitory and the second phase resulting from the interaction between the effects of alcohol and the tumor leads to immune inhibition and resultant tumor progression.

Keywords

Alcohol Antitumor immunity B16BL6 melanoma NK cells T cells NKT cells Metastasis Survival 

Notes

Acknowledgement

This project was supported by K05AA017149 and by funds provided for medical and biological research by the State of Washington Initiative Measure No. 171.

References

  1. 1.
    Nelson DE et al (2013) Alcohol-attributable cancer deaths and years of potential life lost in the United States. Am J Public Health 103(4):641–648PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Boffetta P, Hashibe M (2006) Alcohol and cancer. Lancet Oncol 7(2):149–156PubMedCrossRefGoogle Scholar
  3. 3.
    Haas SL, Ye W, Lohr JM (2012) Alcohol consumption and digestive tract cancer. Curr Opin Clin Nutr Metab Care 15(5):457–467PubMedCrossRefGoogle Scholar
  4. 4.
    Berstad P et al (2008) Alcohol intake and breast cancer risk among young women. Breast Cancer Res Treat 108(1):113–120PubMedCrossRefGoogle Scholar
  5. 5.
    Longnecker MP et al (1995) Risk of breast cancer in relation to lifetime alcohol consumption. J Natl Cancer Inst 87(12):923–929PubMedCrossRefGoogle Scholar
  6. 6.
    Brooks PJ, Zakhari S (2013) Moderate alcohol consumption and breast cancer in women: from epidemiology to mechanisms and interventions. Alcohol Clin Exp Res 37(1):23–30PubMedCrossRefGoogle Scholar
  7. 7.
    Thrift AP et al (2012) The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival. Int J Cancer 131(5):E759–E768PubMedCrossRefGoogle Scholar
  8. 8.
    Mayne ST et al (2009) Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. Cancer Epidemiol Biomarkers Prev 18(12):3368–3374PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Jerjes W et al (2012) The effect of tobacco and alcohol and their reduction/cessation on mortality in oral cancer patients: short communication. Head Neck Oncol 4:6PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Wu IC et al (2012) Substance use (alcohol, areca nut and cigarette) is associated with poor prognosis of esophageal squamous cell carcinoma. PLoS One 8(2):e55834CrossRefGoogle Scholar
  11. 11.
    Wang JB et al (2012) Attributable causes of esophageal cancer incidence and mortality in China. PLoS One 7(8):e42281PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Newcomb PA et al (2013) Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol 31(16):1939–1946PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Kwan ML et al (2012) Postdiagnosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev 22(1):32–41PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Harris HR, Bergkvist L, Wolk A (2012) Alcohol intake and mortality among women with invasive breast cancer. Br J Cancer 106(3):592–595PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Flatt SW et al (2010) Low to moderate alcohol intake is not associated with increased mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 19(3):681–688PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    McDonald PA et al (2002) Breast cancer survival in African American women: is alcohol consumption a prognostic indicator? Cancer Causes Control 13(6):543–549PubMedCrossRefGoogle Scholar
  17. 17.
    Weaver AM et al (2013) Alcohol intake over the life course and breast cancer survival in Western New York exposures and breast cancer (WEB) study: quantity and intensity of intake. Breast Cancer Res Treat 139(1):245–253PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Holm M et al (2013) Pre-diagnostic alcohol consumption and breast cancer recurrence and mortality: results from a prospective cohort with a wide range of variation in alcohol intake. Int J Cancer 132(3):686–694PubMedCrossRefGoogle Scholar
  19. 19.
    Barnett GC et al (2008) Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 26(20):3310–3316PubMedCrossRefGoogle Scholar
  20. 20.
    Morton LM et al (2005) Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol 6(7):469–476PubMedCrossRefGoogle Scholar
  21. 21.
    Tramacere I et al (2012) Alcohol drinking and non-Hodgkin lymphoma risk: a systematic review and a meta-analysis. Ann Oncol 23(11):2791–2798PubMedCrossRefGoogle Scholar
  22. 22.
    Gapstur SM et al (2012) Alcohol intake and the incidence of non-Hodgkin lymphoid neoplasms in the cancer prevention study II nutrition cohort. Am J Epidemiol 176(1):60–69PubMedCrossRefGoogle Scholar
  23. 23.
    Geyer SM et al (2010) Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer 116(12):2993–3000PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Talamini R et al (2008) The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma. Int J Cancer 122(7):1624–1629PubMedCrossRefGoogle Scholar
  25. 25.
    Battaglioli T et al (2006) Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkin’s lymphoma: a population-based study. Ann Oncol 17(8):1283–1289PubMedCrossRefGoogle Scholar
  26. 26.
    Meadows GG et al (1993) Alcohol consumption suppresses metastasis of B16-BL6 melanoma in mice. Clin Exp Metastasis 11:191–199PubMedCrossRefGoogle Scholar
  27. 27.
    Blank SE, Meadows GG (1996) Ethanol modulates metastatic potential of B16BL6 melanoma and host responses. Alcohol Clin Exp Res 20:624–628PubMedCrossRefGoogle Scholar
  28. 28.
    Szabo G, Mandrekar P (2009) A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res 33(2):220–232PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Cook RT (1998) Alcohol abuse, alcoholism, and damage to the immune system—a review. Alcohol Clin Exp Res 22(9):1927–1941PubMedGoogle Scholar
  30. 30.
    Cook RT et al (1991) Activated CD-8 cells and HLA DR expression in alcoholics without overt liver disease. J Clin Immunol 11:246–253PubMedCrossRefGoogle Scholar
  31. 31.
    Song K et al (2002) Chronic ethanol consumption by mice results in activated splenic T cells. J Leukoc Biol 72:1109–1116PubMedGoogle Scholar
  32. 32.
    Laso FJ et al (2007) Chronic alcohol consumption is associated with changes in the distribution, immunophenotype, and the inflammatory cytokine secretion profile of circulating dendritic cells. Alcohol Clin Exp Res 31(5):846–854PubMedCrossRefGoogle Scholar
  33. 33.
    Zhang H, Meadows GG (2005) Chronic alcohol consumption in mice increases the proportion of peripheral memory T cells by homeostatic proliferation. J Leukoc Biol 78(5):1070–1080PubMedGoogle Scholar
  34. 34.
    Abdallah RM, Starkey JR, Meadows GG (1988) Toxicity of chronic high alcohol intake on mouse natural killer cell activity. Res Commun Chem Pathol Pharmacol 59:245–258PubMedGoogle Scholar
  35. 35.
    Núñez NP, Carter PA, Meadows GG (2002) Alcohol consumption promotes body weight loss in melanoma-bearing mice. Alcohol Clin Exp Res 26:617–626PubMedCrossRefGoogle Scholar
  36. 36.
    Zhang H, Meadows GG (2008) Chronic alcohol consumption perturbs the balance between thymus-derived and bone marrow-derived natural killer cells in the spleen. J Leukoc Biol 83(1):41–47PubMedCrossRefGoogle Scholar
  37. 37.
    Weber JS et al (1987) Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J Exp Med 166(6):1716–1733PubMedCrossRefGoogle Scholar
  38. 38.
    Winter H et al (2001) Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol 166(12):7370–7380PubMedCrossRefGoogle Scholar
  39. 39.
    Maeda M et al (1998) Alcohol consumption enhances liver metastasis in colorectal carcinoma patients. Cancer 83(8):1483–1488PubMedCrossRefGoogle Scholar
  40. 40.
    Oksuzler O et al (2009) Investigation of the synergism between alcohol consumption and herpes simplex virus in patients with laryngeal squamous cell cancers. Eur Arch Otorhinolaryngol 266(12):1977–1982PubMedCrossRefGoogle Scholar
  41. 41.
    Wilson SD et al (2011) Zollinger-Ellison syndrome associated with a history of alcohol abuse: coincidence or consequence? Surgery 150(6):1129–1135PubMedCrossRefGoogle Scholar
  42. 42.
    Spitzer JH et al (2000) The modulation of B16BL6 melanoma metastasis is not directly mediated by cytolytic activity of natural killer cells in alcohol-consuming mice. Alcohol Clin Exp Res 24(6):837–844PubMedCrossRefGoogle Scholar
  43. 43.
    Zhang H et al (2011) IFN-gamma is essential for the inhibition of B16BL6 melanoma lung metastasis in chronic alcohol drinking mice. Clin Exp Metastasis 28(3):301–307PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6(11):836–848PubMedCrossRefGoogle Scholar
  45. 45.
    Savage PA, Malchow S, Leventhal DS (2013) Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 34(1):33–40PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Martin F, Apetoh L, Ghiringhelli F (2012) Controversies on the role of Th17 in cancer: a TGF-beta-dependent immunosuppressive activity? Trends Mol Med 18(12):742–749PubMedCrossRefGoogle Scholar
  47. 47.
    Ye J, Livergood RS, Peng G (2013) The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 182(1):10–20PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    DuPage M et al (2012) Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482(7385):405–409PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Shankaran V et al (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832):1107–1111PubMedCrossRefGoogle Scholar
  50. 50.
    Kersh EN et al (2006) Rapid demethylation of the IFN-gamma gene occurs in memory but not naive CD8 T cells. J Immunol 176(7):4083–4093PubMedCrossRefGoogle Scholar
  51. 51.
    Fitzpatrick DR, Shirley KM, Kelso A (1999) Cutting edge: stable epigenetic inheritance of regional IFN-gamma promoter demethylation in CD44highCD8+ T lymphocytes. J Immunol 162(9):5053–5057PubMedGoogle Scholar
  52. 52.
    Winders BR, Schwartz RH, Bruniquel D (2004) A distinct region of the murine IFN-gamma promoter is hypomethylated from early T cell development through mature naive and Th1 cell differentiation, but is hypermethylated in Th2 cells. J Immunol 173(12):7377–7384PubMedCrossRefGoogle Scholar
  53. 53.
    Kambayashi T et al (2003) Memory CD8+ T cells provide an early source of IFN-gamma. J Immunol 170(5):2399–2408PubMedCrossRefGoogle Scholar
  54. 54.
    Laso FJ et al (1999) Chronic alcoholism is associated with an imbalanced production of Th-1/Th-2 cytokines by peripheral blood T cells. Alcohol Clin Exp Res 23(8):1306–1311PubMedCrossRefGoogle Scholar
  55. 55.
    Zhang H, Meadows GG (2010) Chronic alcohol consumption enhances myeloid-derived suppressor cells in B16BL6 melanoma-bearing mice. Cancer Immunol Immunother 59(8):1151–1159PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Highfill SL et al (2010) Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116(25):5738–5747PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Zhu X et al (2014) The central role of arginine catabolism in T-cell dysfunction and increased susceptibility to infection after physical injury. Ann Surg 259(1):171–178PubMedCrossRefGoogle Scholar
  58. 58.
    Vosshenrich CA et al (2006) A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 7(11):1217–1224PubMedCrossRefGoogle Scholar
  59. 59.
    Vivier E et al (2008) Functions of natural killer cells. Nat Immunol 9(5):503–510PubMedCrossRefGoogle Scholar
  60. 60.
    Vivier E et al (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12(4):239–252PubMedCrossRefGoogle Scholar
  61. 61.
    Perney P et al (2003) Specific alteration of peripheral cytotoxic cell perforin expression in alcoholic patients: a possible role in alcohol-related diseases. Alcohol Clin Exp Res 27(11):1825–1830PubMedCrossRefGoogle Scholar
  62. 62.
    Meadows GG et al (1992) Ethanol induces marked changes in lymphocyte populations and natural killer cell activity in mice. Alcohol Clin Exp Res 16:474–479PubMedCrossRefGoogle Scholar
  63. 63.
    Blank SE et al (1993) Ethanol-induced changes in peripheral blood and splenic NK cells. Alcohol Clin Exp Res 17(3):561–565PubMedCrossRefGoogle Scholar
  64. 64.
    Zhang H, Zhu Z, Meadows GG (2011) Chronic alcohol consumption decreases the percentage and number of NK cells in the peripheral lymph nodes and exacerbates B16BL6 melanoma metastasis into the draining lymph nodes. Cell Immunol 266(2):172–179PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Chen S et al (2005) Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J Exp Med 202(12):1679–1689PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Inoue S et al (2006) Inhibitory effects of B cells on antitumor immunity. Cancer Res 66(15):7741–7747PubMedCrossRefGoogle Scholar
  67. 67.
    Yanaba K et al (2008) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28(5):639–650PubMedCrossRefGoogle Scholar
  68. 68.
    Horikawa M et al (2011) Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest 121(11):4268–4280PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    DiLillo DJ, Yanaba K, Tedder TF (2010) B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184(7):4006–4016PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Zhang H, Zhu Z, Meadows GG (2012) Chronic alcohol consumption impairs distribution and compromises circulation of B cells in B16BL6 melanoma-bearing mice. J Immunol 189(3):1340–1348PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Parekh VV et al (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115(9):2572–2583PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674PubMedCrossRefGoogle Scholar
  73. 73.
    Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331(6024):1565–1570PubMedCrossRefGoogle Scholar
  74. 74.
    Saberi Hosnijeh F et al (2010) Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 19(6):1577–1584PubMedCrossRefGoogle Scholar
  75. 75.
    Parekh VV et al (2009) PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 182(5):2816–2826PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Kawamura T et al (2009) NKG2A inhibits invariant NKT cell activation in hepatic injury. J Immunol 182(1):250–258PubMedCentralPubMedCrossRefGoogle Scholar
  77. 77.
    Ota T et al (2005) IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2. Blood 106(1):184–192PubMedCentralPubMedCrossRefGoogle Scholar
  78. 78.
    Fourcade J et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207(10):2175–2186PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Gooden M et al (2011) HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci U S A 108(26):10656–10661PubMedCentralPubMedCrossRefGoogle Scholar
  80. 80.
    Mortier E et al (2009) Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity 31(5):811–822PubMedCrossRefGoogle Scholar
  81. 81.
    Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19(19):5300–5309PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Hui Zhang
    • 1
  • Zhaohui Zhu
    • 1
  • Faya Zhang
    • 1
  • Gary G. Meadows
    • 1
  1. 1.Department of Pharmaceutical SciencesCollege of Pharmacy, Washington State UniversitySpokaneUSA

Personalised recommendations